Azzam Nahla, AlRuthia Yazed, Alharbi Othman, Aljebreen Abdulrahman, Almadi Majid, Alarfaj Maryam, Alsaleh Khalid, Almasoud Abdulaziz, Alsharidah Muhannad, Alseneidi Sarah, Alali Fatimah, Alalwan Malak
Gastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Cancer Manag Res. 2020 Jan 21;12:451-459. doi: 10.2147/CMAR.S233215. eCollection 2020.
Colorectal cancer is the third most common malignancy in Saudi Arabia. The best therapeutic regimen for colorectal cancer is a matter of ongoing debate and data on its treatment in Saudi Arabia are limited.
The objective of this study was to explore the predictors of survival and to compare the risk of mortality among colorectal cancer patients treated with different therapeutic modalities.
The study utilized data from the electronic colorectal cancer registry of a university-affiliated tertiary care hospital. The Kaplan-Meier survival analysis was used to estimate the survival rates over 36 months of follow-up across rectal and colon cancer patients as well as different sociodemographic and medical characteristics. Bivariate and multiple Cox proportional-hazards regressions were conducted to estimate the risk of mortality among rectal and colon cancer patients undergoing different treatments.
The number of patients in the registry who were followed up for 36 months was 143 patients. The majority of patients had colon cancer (74.13%). Rectal cancer patients had generally better survival estimates compared to their colon cancer counterparts. Colon cancer patients treated with chemotherapy had a significantly lower risk of mortality controlling for the use of surgery, radiotherapy, and other variables including age, gender, stage of cancer, and family history of colorectal cancer (HR=0.33; =0.03). Additionally, colon cancer patients with a family history of colorectal cancer had significantly higher risk of mortality (HR=3.40; =0.02).
The findings of this study highlight the value of chemotherapy in managing colon cancer patients.
结直肠癌是沙特阿拉伯第三大常见恶性肿瘤。结直肠癌的最佳治疗方案一直存在争议,且沙特阿拉伯关于其治疗的数据有限。
本研究的目的是探索生存预测因素,并比较接受不同治疗方式的结直肠癌患者的死亡风险。
本研究使用了一家大学附属三级护理医院电子结直肠癌登记处的数据。采用Kaplan-Meier生存分析来估计直肠癌和结肠癌患者以及不同社会人口学和医学特征患者在36个月随访期内的生存率。进行双变量和多变量Cox比例风险回归分析,以估计接受不同治疗的直肠癌和结肠癌患者的死亡风险。
登记处中接受36个月随访的患者有143例。大多数患者患有结肠癌(74.13%)。与结肠癌患者相比,直肠癌患者的生存估计通常更好。在控制手术、放疗及年龄、性别、癌症分期和结直肠癌家族史等其他变量后,接受化疗的结肠癌患者死亡风险显著降低(风险比=0.33;P=0.03)。此外,有结直肠癌家族史的结肠癌患者死亡风险显著更高(风险比=3.40;P=0.02)。
本研究结果突出了化疗在管理结肠癌患者中的价值。